QART (Quantitative Assisted Reproductive Technologies) Medical, a clinical-stage MedTech company, addressing the global infertility epidemic. The Company develops a breakthrough solution for highly informative characterization and selection of sperm cells for in-vitro fertilization (IVF), aiming to create a new and better gold standard in the ART market. The QART system aims to improve current success rates of Intra-Cytoplasmic Sperm Injection (ICSI) by:
Quantitatively characterizing the morphology and contents of individual sperm cells with 3D topographic imaging
Providing quantitative DNA integrity information, on a cell-by-cell basis
Automatically sorting a semen sample according to objective consensus criteria
QART intends to commercially launch its system - a workstation and disposable cartridges - in year 2020, and commence marketing to fertility clinics, aiming to significantly improve pregnancy rates in ICSI procedures.
Prof. Natan T. Shaked, PhD
Chief Scientist, Co-Founder
Associate Professor in the Department of Biomedical Engineering at Tel Aviv University. Was a Visiting Assistant Professor in the Dept. of Biomedical Engineering at Duke University, Durham, NC, USA. Received his BSc, MSc (Summa Cum Laude), and PhD degrees in Electrical and Computer Engineering
Dr. Mattan Levi, PhD
Director Translational Research
Manager of Andrology medical laboratory, Herzliya Medical Center, and prior to that, at the Meir Medical Center. Managed the of Oncology Research Laboratory, headed by Prof. Irit Ben Aharon, Rabin Medical Center and Technion Faculty of Medicine, Israel. Guest scientist in the laboratory of Prof. Natan Shaked at the Department of
BioMed. Eng. at Tel Aviv University.
Shimon Oz, MBA
Chief Financial Officer
M.B.A. in Economics and Business Admin. & Masters Degree in Economics and Business Administration (with honors), Department of Economics, Hebrew University, Jerusalem. Served as an independent adviser acting as executive director and/or CFO, investment banker, and economic consultant for clients including Scitex Corp, Forum Film, Elan Jaglom Group, Mig Group, “Infinity VC Group and Dekora Group, and others.
Dr. Susan Alpert, MD, PhD
Dr. Alpert held the positions of senior vice president and chief regulatory officer at Medtronic until 2012 and a similar role at C.R. Bard. Before Medtronic, she held a number of positions with the FDA including as Director of the FDA’s Office of Device Evaluation. Dr. Alpert holds MD and Ph.D. in infectious diseases from the NYC School of Medicine.